• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the U.S. Market

AmericanPharmaceuticalReviewDecember 10, 2021

Tag: Valsartan , USP , Tablets

Dr. Reddy’s Laboratories Ltd. announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Diovan® brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Dr. Reddy’s Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.

Previous:MHI RJ Aviation Group and Aero HygenX sign a cooperation agreement for Marketing and Distribution of RAY UV-C Robot

Next:Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the U.S. Market | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Misoprostol Tablets 0.2mg

Misoprostol Tablets 0.2mg
Levamisole, Oxyclozanide and Praziquantel oral suspension 3%+6%+2.5%

Levamisole, Oxyclozanide and Praziquantel oral suspension 3%+6%+2.5%
High Quality Collagen tablets

High Quality Collagen tablets
Amoxicilin suspension

Amoxicilin suspension
99% up by HPLC USP GMP DMF Remdesivir 1809249-37-3

99% up by HPLC USP GMP DMF Remdesivir 1809249-37-3
Levofloxacin EP Impurity G(Levofloxacin USP Related Compound E)

Levofloxacin EP Impurity G(Levofloxacin USP Related Compound E)
Aciclovir   Tablets

Aciclovir   Tablets
100% Natural HPLC 95% USP Turmeric Root

100% Natural HPLC 95% USP Turmeric Root
Neomycin sulfate USP EP

Neomycin sulfate USP EP
Lovastatin USPXX III 500g Aluminium Tin

Lovastatin USPXX III 500g Aluminium Tin

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service